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Abstract
© Tyakht et al.; licensee BioMed Central. Background: Human hepatoma HepG2 cells are used
as an in vitro model  of  the human liver.  High-throughput transcriptomic sequencing is  an
advanced approach for assessing the functional state of a tissue or cell type. However, the
influence of experimental factors, such as the sample preparation method and inter-laboratory
variation,  on  the  transcriptomic  profile  has  not  been  evaluated.  Results:  The  whole-
transcriptome sequencing of HepG2 cells was performed using the SOLiD platform and validated
using droplet digital PCR. The gene expression profile was compared to the results obtained with
the same sequencing method in another laboratory and using another sample preparation
method. We also compared the transcriptomic profile HepG2 cells with that of liver tissue.
Comparison of  the  gene expression  profiles  between the  HepG2 cell  line  and liver  tissue
revealed the highest variation,  followed by HepG2 cells  submitted to two different sample
preparation protocols. The lowest variation was observed between HepG2 cells prepared by two
different laboratories using the same protocol. The enrichment analysis of the genes that were
differentially  expressed between HepG2 cells  and liver  tissue mainly  revealed the cancer-
associated gene signature of HepG2 cells and the activation of the response to chemical stimuli
in the liver tissue. The HepG2 transcriptome obtained with the SOLiD platform was highly
correlated with the published transcriptome obtained with the Illumina and Helicos platforms,
with moderate correspondence to microarrays. Conclusions: In the present study, we assessed
the influence of experimental factors on the HepG2 transcriptome and identified differences in
gene expression between the HepG2 cell line and liver cells. These findings will facilitate robust
experimental design in the fields of pharmacology and toxicology. Our results were supported
by a comparative analysis with previous HepG2 gene expression studies.
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